UroGen Pharma Ltd. (URGN) is a publicly traded, clinical-stage biopharmaceutical company dedicated to developing novel therapies designed to change the standard of care for urological pathologies. The company was founded in 2006 with a primary focus on uro-oncology. It is headquartered in Ra'anana, Israel, with U.S. operations based in Princeton, New Jersey, and maintains a public listing on the NASDAQ stock exchange under the symbol "URGN".
UroGen Pharma utilizes its proprietary RTGelTM reverse-thermal hydrogel technology platform to propel the development and commercialization of its product portfolio. This platform allows therapeutic agents to remain in contact with targeted tissues for longer durations, potentially enhancing the treatment effectiveness of existing drugs.
UroGen's lead product, UGN-101 (Mitomycin gel, also known as Jelmyto), is a first-of-its-kind therapeutic approach for the treatment of low-grade upper tract urothelial cancer (LG UTUC). It received approval from the U.S. Food and Drug Administration (FDA) in April 2020, marking a significant milestone for the company. Prior to this, no drugs were approved specifically for LG UTUC, and surgical options often led to significant morbidity.
In addition to UGN-101, UroGen is developing UGN-102 (mitomycin gel), a potentially non-surgical outpatient treatment for low-grade non-muscle invasive bladder cancer (LG NMIBC). This product is currently in phase IIb clinical trials.
UroGen Pharma is led by a team of seasoned professionals with notable expertise in urology, oncology, and drug development. The company is committed to improving the lives of patients by breaking new ground in urologic care and delivering results through relentless scientific and clinical execution.
With its innovative product pipeline and commercialization of its unique platform, UroGen Pharma Ltd. continues to position itself as a leader in providing solutions for overlooked and underserved urological conditions. Through its relentless commitment towards finding innovative solutions for these illnesses, UroGen Pharma Ltd. aims to revolutionize the healthcare system's approach towards urological disorders.
Despite being relatively young, UroGen’s achievements, fuelled by its commitment to excellence and a disruptive approach towards developing solutions, have distinguished it within the biopharmaceutical industry. The future holds promise as UroGen Pharma continues to develop its product pipeline and build on its successes.